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B  cells are central to the pathogenesis of granulomatosis with polyangiitis (GPA), 
exhibiting both (auto)antibody-dependent and -independent properties. Class-switched 
memory B cells in particular are a major source of pathogenic autoantibodies. These 
cells are characterized by high expression levels of Kv1.3 potassium channels, which 
may offer therapeutic potential for Kv1.3 blockade. In this study, we investigated the 
effect of the highly potent Kv1.3 blocker ShK-186 on B cell properties in GPA in vitro. 
Circulating B cell subsets were determined from 33 GPA patients and 17 healthy con-
trols (HCs). Peripheral blood mononuclear cells (PBMCs) from GPA patients, and HCs 
were stimulated in vitro in the presence and absence of ShK-186. The production of 
total and antineutrophil cytoplasmic antibodies targeting proteinase 3 (PR3-ANCA) IgG 
was analyzed by enzyme-linked immunosorbent assay and Phadia EliA, respectively. In 
addition, effects of ShK-186 on B cell proliferation and cytokine production were deter-
mined by flow cytometry. The frequency of circulating switched and unswitched memory 
B cells was decreased in GPA patients as compared to HC. ShK-186 suppressed the 
production of both total and PR3-ANCA IgG in stimulated PBMCs. A strong decrease 
in production of tumor necrosis factor alpha (TNFα), interleukin (IL)-2, and interferon 
gamma was observed upon ShK-186 treatment, while effects on IL-10 production were 
less pronounced. As such, ShK-186 modulated the TNFα/IL-10 ratio among B cells, 
resulting in a relative increase in the regulatory B  cell pool. ShK-186 modulates the 
effector functions of B cells in vitro by decreasing autoantibody and pro-inflammatory 
cytokine production. Kv1.3 channel blockade may hold promise as a novel therapeutic 
strategy in GPA and other B cell-mediated autoimmune disorders.
Keywords: granulomatosis and polyangiitis, B  cells, Kv1.3 potassium channels, antineutrophil cytoplasmic 
antibody, cytokines
Abbreviations: AAV, ANCA-associated vasculitis; APRIL, a proliferation-inducing ligand; BAFF, B  cell-activating factor; 
BVAS, Birmingham Vasculitis Activity Score; CD, cluster of differentiation; ELISA, enzyme-linked immunosorbent assay; GPA, 
granulomatosis with polyangiitis; HC, healthy control; Ig, immunoglobulin; IFNγ, interferon gamma; IL, interleukin; MMF, 
mycophenolate mofetil; PR3-ANCA, antineutrophil cytoplasmic antibodies targeting proteinase 3; RA, rheumatoid arthritis; 
SLE, systemic lupus erythematous; TNFα, tumor necrosis factor alpha.
TaBle 1 | Clinical and laboratory characteristics of the granulomatosis with 
polyangiitis (GPA) patients at the time of blood sampling.
gPa patients
Subjects, n (% male) 33 (45)
Age, mean (range) 57 (26–85)
Antineutrophil cytoplasmic antibodies targeting proteinase 3 
(PR3-ANCAa), n (% positive)
28 (85)
PR3-ANCA titer, median (range) 1:80 (0 to >640)
eGFR ml/min × 1.73 m2, median (range) 65 (13–111)
Disease duration in years, median (range) 12.5 (2.8–31.3)
Number of previous relapses, median (range) 2 (0–10)
Non/maintenance immunosuppressive therapy,b n 20/13
aANCA-positive titer ≥1:40, ANCA-negative ≤1:20.
bMaintenance immunosuppressive therapy: azathioprine, azathioprine + prednisolone, 
prednisolone, mycophenolate mofetil + prednisolone, or methotrexate.
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inTrODUcTiOn
Granulomatosis with polyangiitis (GPA) is a severe autoimmune 
form of necrotizing small vessel vasculitis characterized by the 
presence of antineutrophil cytoplasmic antibodies (ANCAs) 
(1, 2). GPA patients frequently present with circulating ANCAs 
directed against the neutrophil constituent proteinase 3 (PR3). 
Several observations suggest that antineutrophil cytoplasmic 
antibodies targeting proteinase 3 (PR3-ANCA) play an important 
role in the pathophysiology of GPA. For example, leukocytes acti-
vated by ANCA release mediators that can injure endothelial cells 
in vitro and activation of neutrophils by ANCA can stimulate the 
release of neutrophil extracellular traps that contain chromatin 
and proteins including PR3. As B  cells are the progenitors of 
ANCA-producing plasma cells (3), targeting B cells is an interest-
ing therapeutic option for GPA.
Currently, patients are usually treated with broadly acting 
immunosuppressives. This strategy consists of cyclophospha-
mide and corticosteroids for induction therapy, often followed by 
azathioprine or mycophenolate mofetil (MMF) as maintenance 
treatment (4). While the introduction of immunosuppres-
sive treatment has significantly improved the survival of GPA 
patients, severe adverse events are common, such as high rates of 
infections, thromboembolic complications, and drug toxicity (5). 
This emphasizes the need for more specific and less toxic treat-
ment regimens for GPA patients. More recently, the anti-CD20 
monoclonal antibody rituximab has been approved for induction 
therapy in ANCA-associated vasculitis. Rituximab was found to 
be non-inferior to standard cyclophosphamide treatment for 
induction of remission (6, 7). However, it was not possible to 
indicate rituximab as a clearly safer alternative to cyclophospha-
mide, as adverse event rates were similar (8). Moreover, there is a 
risk of persistent severe hypogammaglobulinemia and associated 
infections after rituximab treatment, necessitating IgG replace-
ment therapy (9). Rituximab indiscriminately depletes all B cells, 
which may not be ideal as it has become evident that antibody-
independent functions of B  cells are also important in GPA 
(10). Certain B cells can exert regulatory functions, for example, 
through production of the regulatory cytokine interleukin (IL)-10 
(11, 12). Conversely, B cells can also produce a variety of effector 
cytokines (13). Therefore, selectively targeting pro-inflammatory 
B cells without impairing the regulatory function of B cells may 
be preferable to targeting all B cells. As class-switched memory 
B cells have a higher propensity to undergo plasma cell differen-
tiation and are important in the amplification and maintenance 
of autoimmune responses (14), targeting these B cells may hold 
therapeutic promise for autoimmune diseases in general and for 
GPA patients in particular.
It has been demonstrated that class-switched memory B cells 
express a significantly higher number of voltage-gated Kv1.3 
potassium channels compared to other B cell subsets. These Kv1.3 
channels can serve as a therapeutic target for modulation of class-
switched memory B cell function (15). Similar to T cells, B cells 
use the Kv1.3 channels to regulate Ca2+ signaling by controlling 
the membrane potential. Activation of these lymphocytes induces 
intracellular Ca2+ release from internal stores. Depletion of these 
intracellular Ca2+ stores results in an influx of extracellular Ca2+. 
The driving force for Ca2+ entry is maintained by a counterbal-
ance of K+ efflux mediated by Kv1.3 channels. This mechanism 
sustains elevated cytosolic Ca2+ levels required for optimal lym-
phocyte activation (16, 17). A potent peptide inhibitor of Kv1.3 
channels termed ShK-186 has been identified and investigated 
for its modulatory effects on T cells (18). Considering the high 
expression levels of Kv1.3 channels on switched memory B cells, 
we hypothesized that blockade of these channels would result 
in inhibition of B cell effector functions. Therefore, we investi-
gated the effect of Kv1.3 channel blockade on B cells in vitro, by 
determining its effect on ANCA production, B cell proliferation, 
and production of pro- and anti-inflammatory cytokines in GPA 
patients and healthy controls (HCs).
MaTerials anD MeThODs
study Population
Thirty-three PR3-ANCA-positive GPA patients (Table  1) and 
17 age- and sex-matched HCs (8 males, 9 females, mean age 
55.6  years, range 44.0–74.1  years) were enrolled in this cross-
sectional study. The diagnosis of GPA was established according 
to the definitions of the Chapel Hill Consensus Conference (19), 
and all patients fulfilled the classification criteria of the American 
College of Rheumatology (20). Only patients without clinical 
signs and symptoms of active vasculitis and considered to be in 
complete remission, as indicated by the Birmingham Vasculitis 
Activity Score of 0 (21), were included in this study. None of 
the patients and controls experienced an infection at the time of 
sampling.
At the time of inclusion, three GPA patients received aza-
thioprine, one patient received azathioprine in combination 
with prednisolone, five patients were treated with low dose 
prednisolone, three patients received low dose prednisolone 
in combination with MMF, and one patient was treated with 
methotrexate. All patients had previously received a combination 
of cyclophosphamide with prednisolone as remission induction 
therapy for at least 12  months prior to their inclusion in this 
study. One patient received additional treatment with rituximab 
1 year before inclusion, and two patients 5 years before inclusion 
(B cells were reconstituted in all). All subjects provided written 
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informed consent and the study was approved by the Medical 
Ethical Committee of the University Medical Center Groningen. 
The main clinical and laboratory data of the patients are listed in 
Table 1.
Flow cytometry immunophenotyping  
for B cells
EDTA blood samples from GPA patients and HCs were washed 
twice with PBS + 1% BSA to remove plasma proteins. Next, 100 µl 
of the cell suspension was stained with CD19-eFluor450, CD27-
APC-eFluor780 (both eBioscience, San Diego, CA, USA), IgD-PE 
(BD Biosciences, Franklin Lakes, NJ, USA), or the corresponding 
isotype controls. After 15 min, cells were fixed and erythrocytes 
were lysed using FACS lysing solution. Samples were washed 
and measured using an LSR-II flow cytometer (BD Biosciences) 
and data were analyzed using Kaluza 1.2 flow analysis software 
(Beckman Coulter, Brea, CA, USA). B cells were divided based on 
their surface expression of IgD and CD27. Results are expressed 
as percentages of total CD19+ B cells.
induction and Measurement of Total  
and Pr3-anca-specific igg
Cell culture and quantification of total and PR3-ANCA IgG was 
performed as previously described by our group (22). Briefly, 
peripheral blood mononuclear cells (PBMCs) were isolated from 
GPA patients, who produce ANCA upon in vitro induction (20), 
and stored in RPMI 1640 (Lonza, Basel, Switzerland) supple-
mented with 50 µg/mL gentamycin (GIBCO, Life Technologies, 
Grand Island, NY, USA), 10% fetal calf serum (FCS, Lonza), 
and 10% dimethyl sulfoxide (DMSO). Cryopreserved PBMCs 
were thawed, and cell suspensions were adjusted to 106 cells/
ml in RPMI +  10% FCS. Cells were seeded in 48-well plates 
(Corning, NY, USA) and stimulated with 3.2  µg/ml CpG-
oligodeoxynucleotides (ODN) 2006 (Hycult Biotech, Uden, the 
Netherlands), 100 ng/ml B cell-activating factor (BAFF; PeproTech 
Inc., Rocky Hill, NJ, USA), and 100 ng/ml IL-21 (Immunotools, 
Friesoythe, Germany) at 37°C with 5% CO2, in the presence and 
absence of 1 nM ShK-186 (Kineta Inc., Seattle, WA, USA). After 
12 days, the culture supernatants were harvested and levels of both 
total IgG and PR3-ANCA IgG were determined using in-house 
enzyme-linked immunosorbent assay and Phadia ImmunoCAP 
250 analyzer with EliA PR3S (Thermo Fisher Scientific, Waltham, 
MA, USA), respectively. Levels of PR3-ANCA IgG are expressed 
as response units (RU) per milliliter.
B cell Proliferation assay
Thawed PBMC from GPA patients and HCs were stained with 
2.5 µg/ml carboxyfluorescein diacetate succinimidyl ester (CFSE; 
Invitrogen, Life Technologies). Cells were then cultured at a 
concentration of 106 cells/ml in RPMI + 10% FCS and stimulated 
using 3.2 µg/ml CpG-ODN 2006, 100 ng/ml BAFF, and 100 ng/
ml IL-21, in the presence and absence of 1 nM ShK-186. After 
4 days of incubation, cells were harvested, washed, and labeled 
with CD19-eFluor450, CD22-APC (BD Biosciences) and pro-
pidium iodide (BD Biosciences). Samples were measured using 
an LSR-II flow cytometer, and data were analyzed with Kaluza 
1.2 software. The CFSE staining intensity of unstimulated B cells 
was used to determine the percentage of proliferated B  cells. 
Proliferated B cells are expressed as the percentage of B cells that 
have undergone at least one round of cell division.
cells stimulation and Measurement  
of intracellular B cell cytokines
Thawed PBMCs were seeded in 24-well flat bottom plates 
(Corning) at 106 cells/ml in RPMI  +  10% FCS. Cells were 
stimulated with 500  ng/ml CpG-ODN 2006 in the presence 
and absence of 1  nM ShK-186. Plates were incubated for 72  h 
at 37°C with 5% CO2. During the last 5  h of incubation, cells 
were restimulated with 50  ng/ml phorbol myristate acetate 
(PMA; Sigma-Aldrich, St. Louis, MO, USA) and 2 mM calcium 
ionophore (Sigma-Aldrich). As a negative control, one sample 
was kept without restimulation. To inhibit cytokine release 
from cells, 10  µg/ml brefeldin A (Sigma-Aldrich) was added 
to each sample. Subsequently, cells were harvested, washed 
with PBS +  5% FCS, and stained using CD19-eFluor450 and 
CD22-PeCy5 (Biolegend, San Diego, CA, USA). Next, cells were 
fixed, washed, permeabilized using an Invitrogen Fix&Perm kit, 
and stained with IL-10-PE (Biolegend), tumor necrosis factor 
alpha (TNFα)-Alexa Fluor 488 (BD Biosciences), IL-2-PeCy7 
(eBioscience), and interferon gamma (IFNγ)-Alexa Fluor 700 
(BD Biosciences). Samples were measured using an LSR-II flow 
cytometer, and data were analyzed with Kaluza 1.2. Samples that 
were not stimulated with PMA + calcium ionophore were used as 
negative controls in order to set gates during data analysis. Data 
are presented as the total percentage of cytokine-positive cells 
within the CD19+CD22+ B cell population.
statistical analysis
Statistical analysis was performed using SPSS v22 (IBM 
Corporation, Chicago, IL, USA) and Graphpad Prism v5.0 
(GraphPad Software, San Diego, CA, USA). Data are presented 
as median values with an interquartile range unless stated 
otherwise. Data were analyzed with the D’Agostino and Pearson 
omnibus normality test for Gaussian distribution. For compari-
son between groups, the unpaired t-test was used for data with 
Gaussian distribution and the Mann–Whitney U test for data 
without Gaussian distribution. For paired comparisons, the paired 
t-test or Wilcoxon matched pairs test were applied for Gaussian 
and non-Gaussian data, respectively. Correlation analysis was 
performed using the Spearman rank correlation coefficient. 
p Values <0.05 were considered statistically significant.
resUlTs
Distribution of circulating B cell subsets 
in gPa
To evaluate the distribution of different B cell subsets, phenotypic 
characterization of circulating B cell populations was performed 
on blood samples from 33 GPA patients and 17 matched HC. 
B cells were identified using CD19 and surface expression of CD27 
and IgD was used to distinguish four B cell subsets; IgD+CD27− 
transitional/naive B  cells, IgD+CD27+ unswitched memory 
FigUre 1 | Phenotypic characterization of circulating B cell subsets in granulomatosis with polyangiitis (GPA) patients and healthy controls (HCs). (a) Flow 
cytometry gating strategy to distinguish differentiation subsets within peripheral blood CD19+ B cells. IgD+CD27− transitional/naive B cells, IgD+CD27+ unswitched 
memory B cells, IgD−CD27+ switched memory B cells and IgD−CD27− double negative B cells were identified. (B) Relative distribution of distinct CD19+ B cells 
subsets from HCs (open circles) and GPA patients (gray circles). Horizontal lines indicate median values. Graphs represent data of 17 HCs and 33 GPA patients 
(**p < 0.01, ***p < 0.001).
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B  cells, IgD−CD27+ switched memory B  cells, and IgD−CD27− 
double negative B  cells (Figure  1A). The percentage of double 
negative B  cells did not differ between GPA patients (median 
4.4, interquartile range 2.6–6.7%) and HC (4.5, 2.6–7.8%). An 
increased proportion of transitional/naive B cells was detected in 
GPA (88, 81–91%) compared to HC (74, 70–84%). Finally, GPA 
patients had lower percentages of both switched (3.4, 2.1–5.5% vs. 
7.5, 4.5–9.3%) and unswitched memory B cells (3.3, 2.4–6.0% vs. 
9.2, 8.0–14%) compared to HCs (Figure 1B).
shK-186 inhibits Pr3-anca igg 
Production In Vitro
We next evaluated the effect of Kv1.3 channel blockade on the 
production of total and PR3-ANCA IgG by B cells in vitro. To 
investigate this, we performed our previously established method 
for inducing ANCA production in vitro by specific stimulation of 
B cells using CpG-ODN, IL-21, and BAFF (22). Only cells from 
GPA patients that produced ANCA in vitro were included in this 
study. PBMC from 13 GPA patients and 5 HCs were cultured in 
the presence and absence of ShK-186. Addition of 1  nM ShK-
186 only at the start of the cell culture resulted in a significantly 
decreased production of total IgG (23, 15–40 µg/ml) compared to 
PBMCs cultured without ShK-186 (38, 26–52 µg/ml) in HC sam-
ples. IgG production from GPA patient samples (17, 11–23 µg/
ml) was similarly reduced by treatment with 1  nM ShK-186 
(11, 8–19  µg/ml) (Figure  2A). The effect of ShK-186 on IgG 
production was dose dependent (Figure S1A in Supplementary 
Material). Additionally, PR3-ANCA specific IgG production 
(40, 20–100 RU/ml) was significantly inhibited by ShK-186 (29, 
3–120 RU/ml) in GPA samples (Figure 2B). Five patients showed 
a strong reduction in PR3-ANCA-specific IgG production by 
ShK-186. In seven patients, the effect of ShK-186 on the PR3-
ANCA IgG was intermediate to limited, whereas inexplicable, 
one patient showed increased PR3-ANCA production after treat-
ment with 1 nM ShK-186. Overall, the effect of ShK-186 appeared 
to be more pronounced on PR3-ANCA IgG production (median 
reduction of 39%) than on total IgG production (23%) in samples 
from GPA patients.
Production of total IgG in GPA correlated positively with the 
presence of IgD−CD27+ switched memory B  cells (spearman’s 
rho = 0.62, p = 0.025), while production of PR3-ANCA-specific 
IgG did not (spearman’s rho = 0.03, p = 0.92), nor did production 
of PR3-ANCA IgG correlate with other B cell populations.
shK-186 Does not affect B cell 
Proliferation
To determine whether the decreased production of IgG and 
PR3-ANCA upon ShK-186 treatment occurs due to decreased 
B cell proliferation, the effect of ShK-186 on B cell proliferation 
was assessed in samples from 11 GPA patients and 5 HCs. As 
expected, stimulation of PBMC with CpG, BAFF, and IL-21 
induced B cell proliferation (Figure 3), whereas no such prolif-
eration was observed in other lymphocytes (data not shown). As 
shown in Figure 3B, proliferation of B cells from GPA patients 
was not suppressed by addition of 1 nM ShK-186. Similar results 
were obtained in HC samples without and with 1 nM ShK-186 
(Figure 3B). There was no difference in the percentage of apop-
totic B  cells between cultures of GPA patient and HC samples 
with or without ShK-186 incubation (Figure S2 in Supplementary 
Material). These data indicate that the reduced IgG production 
upon ShK-186 treatment is not caused by decreased B  cell 
proliferation.
shK-186 suppresses Pro-inflammatory 
cytokine Production by B cells with Minor 
effect on anti-inflammatory il-10 
expression
In addition to antibody production, B cells can also participate 
in orchestrating the immune response by producing a wide 
range of pro- and anti-inflammatory cytokines. Therefore, we 
determined whether cytokine production by circulating effec-
tor B cells (TNFα, IFNγ, and IL-2) or regulatory B cells (IL-10) 
FigUre 3 | ShK-186 does not affect B cell proliferation. (a) Representative histograms of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled B cells 
from one granulomatosis with polyangiitis (GPA) patient showing the effect of 96 h treatment with CpG, B cell-activating factor (BAFF), and interleukin (IL)-21 on 
B cell proliferation in the presence and absence of 1 nM ShK-186 (solid lines). Dashed lines represent unstimulated CFSE-labeled B cells. (B) Percentages of 
CD19+CD22+ B cells that have undergone at least one division after 96 h stimulation with CpG BAFF and IL-21 in the presence and absence of 1 nM ShK-186 from 
healthy controls (HCs) (open circles) and GPA patients (gray circles). Horizontal lines indicate median values. Graphs represent data of 5 HCs and 11 GPA patients.
FigUre 2 | ShK-186 inhibits antineutrophil cytoplasmic antibodies targeting proteinase 3 (PR3-ANCA) production in vitro. (a) IgG production after peripheral  
blood mononuclear cell (PBMC) stimulation with CpG, B cell-activating factor (BAFF), and interleukin (IL)-21 from 5 healthy controls (HCs) (open circles) and 13 
granulomatosis with polyangiitis (GPA) patients (gray circles) in the presence and absence of 1 nM ShK-186. (B) PR3-ANCA production after PBMC stimulation  
with CpG, BAFF, and IL-21 from 13 GPA patients in the presence and absence of 1 nM ShK-186 (*p < 0.05, **p < 0.01).
5
Land et al. Kv1.3-Blockade Modulates B cells in GPA
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1205
was influenced by blockade of the Kv1.3 channel (Figure 4A). 
Samples from 21 GPA patients and 12 HCs were stimulated 
in the presence and absence of ShK-186 and B  cell cytokine 
production was assessed. As shown in Figure 4B, addition of 
ShK-186 to cell cultures significantly reduced the production 
of TNFα, IL-2, and IFNγ in samples from both HCs and GPA 
patients. The effect of ShK-186 on production of TNFα, IL-2, 
and IFNγ was dose dependent in both GPA and HC samples 
(Figure S1B in Supplementary Material). For IL-10, no sig-
nificant effect of ShK-186 was observed in HC samples while 
in B cells from GPA patients a significant reduction was found 
(Figure 4B). Remarkably, the suppressive effect of ShK-186 on 
IL-10 production was less pronounced than that on TNFα, IL-2, 
and IFNγ.
Next, we assessed whether ShK-186 modulates the ratio 
of effector B  cells to regulatory B  cells. In this analysis, we 
defined effector B cells as TNFα+IL-10− and regulatory B cells as 
TNFα−IL-10+ cells. The B effector:B regulatory ratio was signifi-
cantly decreased after treatment with ShK-186 in GPA patients 
and HCs (Figure 4C).
Since activated T  cells also upregulate Kv1.3 channels, one 
could argue that the observed effect on B cell cytokine production 
is due to the inhibitory effect of ShK-186 on activated T cells. To 
elucidate whether the beneficial effect of ShK-186 on B cells is 
T-cell dependent or independent, we performed a T-cell deple-
tion experiment as described in Figure S3 in Supplementary 
Material. The results indicate that ShK-186 can modulate the 
production of B cell pro-inflammatory cytokines in the absence 
FigUre 4 | Effect of ShK-186 on intracellular cytokine production by circulating B cells. (a) Representative flow cytometry dot plots of cytokine production in 
CD19+CD22+ B cells from a granulomatosis with polyangiitis (GPA) patient. Upper panel represents cytokine production after CpG stimulation; lower panel 
represents cytokine production after CpG stimulation in the presence of 1 nM ShK-186. (B) Percentages of cytokine producing B cells after stimulation with CpG in 
the presence and absence of 1 nM ShK-186 from healthy controls (HCs) (upper panel) and GPA patients (lower panel). Horizontal lines indicate median values. 
Graphs represent data of 12 HCs and 21 GPA patients. (c) For all GPA patients and HC, the single-positive B cells for either tumor necrosis factor alpha (TNFα) or 
interleukin (IL)-10 were determined in the presence and absence of 1 nM ShK-186 (left panel) and the TNFα/IL-10 ratio was calculated (right panel) (**p < 0.01, 
***p < 0.001).
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of T cells indicating that the effect of ShK-186 on B cell cytokine 
production is not caused by an indirect effect on T cells.
DiscUssiOn
Granulomatosis with polyangiitis is a relatively rare but deadly 
disease when left untreated. Current treatment is unsatisfactory 
as it includes strong immunosuppressives with many severe 
side effects and is not always effective (23). Therefore, selective 
targeting of pathogenic pathways may hold therapeutic promise 
for GPA patients. Given the proposed pathogenic role of B cells 
and ANCA in GPA, total B cell depletion with rituximab seems 
a logical strategy for treatment. However, as a fraction of B cells 
exerts regulatory functions, it is important to identify a targeting 
strategy that can specifically inhibit effector functions of B cells, 
leaving suppressor aspects intact. Here, we evaluated the effect of 
blocking Kv1.3 channels, which are highly expressed by switched 
memory B cells, on (auto)antibody production, proliferation, and 
production of pro- and anti-inflammatory cytokines in B  cells 
from GPA patients.
In the present study, we confirm previously described differ-
ences in the distribution of circulating B cell subset between GPA 
patients in remission and HC (22, 24). We observed a diminished 
percentage of circulating CD27+ memory B cells and an increased 
percentage of transitional/naïve B cells in GPA patients. A decrease 
in circulating memory B cells most likely represents an enhanced 
differentiation toward plasma cells (25, 26) or selective migration 
to inflammatory sites. B cell clusters have indeed been observed in 
granulomatous lesions of GPA patients (27). Therefore, we cannot 
exclude the possibility that the altered proportion of circulating 
B cell subsets in GPA patients occur due to migration of memory 
B cells toward inflamed tissue sites.
Differences in potassium channel expression on the surface of 
B cell subsets may contribute to changes in Ca2+ signaling patterns 
which influence the function of distinct B cell subsets as it does 
for T cell subsets (16, 17). Lymphocyte activation results in Ca2+ 
induced signaling pathways mediate via Kv1.3 channels. It has 
been demonstrated that the biophysical properties of Kv1.3 chan-
nels in human B cells parallels those in T cells (15). For instance, 
activation of switched memory B cells induces intracellular Ca2+ 
release from internal stores. Depletion of these Ca2+ stores causes 
calcium release-activated calcium channels to open the mem-
brane, resulting in a Ca2+ influx. The driving force for Ca2+ entry 
is maintained by a counterbalance of K+ efflux mediated by Kv1.3 
channels. This mechanism sustains elevated cytosolic Ca2+ levels 
required for optimal B cell activation affecting cellular processes 
such as (auto)antibody and cytokine production.
Blocking Kv1.3 channels on activated B cells in vitro inhibits 
the production of both total and PR3-ANCA-specific IgG. The 
mechanisms behind this effect are not fully understood. It has 
been shown that Kv1.3 channels on B cells are mainly expressed 
on IgD−CD27+ switched memory B  cells (15), and total IgG 
production in vitro was indeed associated with this B cell subset. 
This association indicates that direct inhibition of switched 
memory B cells may explain the decreased production of total 
IgG. However, production of PR3-ANCA-specific IgG was not 
positively associated with the IgD−CD27+ B  cell subset. The 
difference in the amount of autoreactive B  cells present in the 
cultured samples could explain why IgD−CD27+ B cells not corre-
lated with PR3-ANCA IgG. Interestingly, the production of total 
IgG was not completely inhibited by ShK-186. This might indicate 
that not all IgG-producing B cells were equally influenced by the 
Kv1.3-blocker, which can be considered as an advantage for this 
treatment. Consistent with our finding, Matheu and co-workers 
have demonstrated that the efficacy of ShK-186 is achieved 
without generalized immunosuppression in vivo (28). Proof-of-
concept studies in rats showed a normal clearance of influenza 
virus and Chlamydia infection after treatment with ShK-186, 
whereas clearance of these infections was significantly delayed 
in rats treated with steroids (28). Thus, these studies might sug-
gest that ShK-186 does not compromise the protective immune 
response against acute infectious agents.
Nevertheless, in the majority of patients, addition of ShK-186 
did result in reduction of PR3-ANCA IgG production in vitro. A 
plausible explanation for the effect of ShK-186 on PR3-ANCA 
IgG production is that Kv1.3 channel blockade reduces the num-
ber of plasma cells formed in  vitro, thus affecting the number 
of cells producing (PR3-ANCA) IgG. However, total B cell pro-
liferation was not affected by ShK-186, suggesting that reduced 
proliferation is not the underlying cause for the lower IgG levels 
observed. It is also highly unlikely that the observed reduction in 
PR3-ANCA production is owing to the inhibitory effect of ShK-
186 on activated memory T cells, as only B cells are activated by 
CpG in vitro. Therefore, the in vitro culture system present in this 
study provides a useful tool to investigate immunomodulation of 
(auto)antibody-producing B cells.
In contrast to our study, Wulff et  al. previously reported an 
inhibitory effect of ShK on proliferation of B cells (15). They dem-
onstrated that proliferation of IgD− B  cells (switched memory 
B  cells) was suppressed in a dose-dependent manner, whereas 
proliferation of IgD+ B  cells (including naïve and unswitched 
memory B  cells) was inhibited only when using a high dose 
(100 nM) of ShK. Differences in methodology, stimulation condi-
tions, and most likely B cell source, may be potential explanations 
for this apparent discrepancy between the studies. In their study, 
Wulff et al. used for their proliferation experiment human tonsil-
lar CD19+ B cells and separated the B cell fraction into IgD+ cells 
(including naïve and unswitched memory B cells) and IgD− cells 
(switched memory B cells). In our study, PBMCs were isolated 
from whole blood from patients and HCs. As shown in Figure 1, 
88% of B cells from GPA patients and 74% of B cells from HC 
within the PBMCs fraction consist of transitional/naïve B cells, 
which according to the report by Wulff et al., are less prone to 
be suppressed in proliferation by ShK compared to IgD+ B cells. 
Therefore, in our study, the large proportion of naïve B cells within 
the total B cell population may have masked the suppressive effect 
of ShK-186 on switched memory B cells.
Production of cytokines by B cells was also clearly inhibited 
when samples were treated with ShK-186. This effect appeared to 
be more pronounced on the effector cytokines TNFα, IL-2, and 
IFNγ than on the regulatory cytokine IL-10. Indeed, when the 
TNFα/IL-10 ratio was determined, this significantly decreased 
upon treatment with ShK-186. The decrease in the TNFα/IL-10 
ratio suggests that Kv1.3 channel blockade results in a relative 
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increase of regulatory B  cell phenotype compared to effector 
B cells. This may have positive effects in the treatment of patients 
with autoimmunity, as ShK-186 modulates the B  cell response 
toward a suppressive phenotype.
The importance of targeting memory B  cells is emphasized 
by the (lack of) efficacy of B cell-directed therapies. Treatment 
strategies affecting B cell survival, comprised of anti-BAFF with 
or without simultaneous blockade of a proliferation-inducing 
ligand (i.e., belimumab, tabalumab, and atacicept), have failed to 
show sufficient efficacy in clinical trials for treatment of systemic 
lupus erythematosus, rheumatoid arthritis (RA), and multiple 
sclerosis (29–34). Although these agents target mature B cells and 
short-lived plasma cells, the memory B cells are spared (35), and 
especially switched memory B cells appear to be resistant to BAFF 
depletion (36). By contrast, anti-CD20 B  cell depleting studies 
using rituximab show beneficial outcomes for patients with GPA 
and RA (6, 37). However, disease flares have been observed in 
patients with RA when the memory B  cell population returns 
following rituximab therapy (38). Thus, the current therapeutic 
agents do not adequately target memory B  cells, but instead 
largely affect naïve B cells.
One could argue that only patients in remission, but not 
during active disease, have been included in this study. It has 
been suggested that upon active disease memory B cells migrate 
from the circulation into inflamed tissues of the upper airways 
or kidneys as a result of infectious triggers (25). Since migration 
of circulating memory B cells during active disease could alter 
the B cell subset distribution and exclude them from examina-
tion, this study was therefore focused on GPA patients during 
clinical remission. Furthermore, the stimulation conditions used 
in vitro in this study may mimic the stimulation by bacterial CpG 
motifs of autoreactive B cells inducing a pro-inflammatory milieu 
and ANCA production in vivo. However, studying patients with 
active disease would certainly be of interest.
cOnclUsiOn
Considering the high expression of Kv1.3 channels on the surface 
of switched memory B cells and their involvement in autoimmune 
disorders, specific Kv1.3 channel blockade could be an attractive 
therapeutic target. Here, we demonstrate that ShK-186 is capable 
of inhibiting (auto)antibody and pro-inflammatory cytokine pro-
duction in vitro, whereas production of the regulatory cytokine 
IL-10 was less affected. These results support the contention that 
selective targeting of Kv1.3 channels using ShK-186 may hold 
therapeutic promise for GPA.
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